|Slideshows|May 13, 2020

Identifying and Managing Pain in Cognitively Impaired Patients

How can clinicians determine the presence of pain in cognitively impaired patients? And how do you know the medication is working if your patient can’t tell you?

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Podcast: How to Mindfully Prescribe Benzodiazepines With Carl Salzman, MD

ByJoseph F. Goldberg, MD,Carl Salzman, MD

August 28th 2026

Modified Titration Dosing Reduces ARIA-E Risk With Donanemab, A Discussion With John Sims, MD

ByJessica Walters,John Sims, MD

August 28th 2026

Diagnosing and Treating Alzheimer Disease: August's Key Developments

ByJessica Walters

August 27th 2026

Biomarker Testing for Alzheimer Disease: Inside the Latest P-Tau217 Data

ByAnthony Sireci, MD,Jessica Walters

August 27th 2026

Benzodiazepines in Older Adults: Alzheimer Risk, Memory, and Beers Criteria

ByJoseph F. Goldberg, MD,Carl Salzman, MD

August 26th 2026

Latest CME

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Register now!

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

Identifying and Managing Pain in Cognitively Impaired Patients

Related Content

Podcast: How to Mindfully Prescribe Benzodiazepines With Carl Salzman, MD

Modified Titration Dosing Reduces ARIA-E Risk With Donanemab, A Discussion With John Sims, MD

Diagnosing and Treating Alzheimer Disease: August's Key Developments

Biomarker Testing for Alzheimer Disease: Inside the Latest P-Tau217 Data

Benzodiazepines in Older Adults: Alzheimer Risk, Memory, and Beers Criteria

Latest CME

Jersey City Psychiatry

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Trending on Psychiatric Times

Phase 2 Trial of Bezisterim for Neurological Symptoms of Long COVID: Treatment Phase Completed

New Research Explores the Genetic Roots of Hair-Pulling and Skin-Picking, Connection to OCD

When Treatment-Resistant Depression Means Mismatched: Rethinking Difficult-to-Treat Depression

International Overdose Awareness Day Marks 25th Year as US Overdose Deaths Decline Yet Remain High

August 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News